An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa
The development of prademagene zamikeracel represents a significant advance in regenerative therapy for RDEB, demonstrating that durable restoration of C7 expression and long-term wound improvement can be achieved through skin grafting.
Authors
- Aleksandra Lesiak (ORCID: https://orcid.org/0000-0003-3318-729X)
- M Peter Marinkovich
Institutions
- Medical University of Lodz (PL)
- Stanford University (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1080/14712598.2026.2639393
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00